Stocklytics Platform
InMed Pharmaceuticals
INM65
$2.68arrow_drop_up1.12%$0.03
Penny Stock
INM65

$2.68

arrow_drop_up1.12%

Performance History

no data available for performance history chart

There's no data available for performance history chart

Key Stats
Open$2.73
Prev. Close$2.67
EPS-12.42
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.24M
PE Ratio-
LOWHIGH
Day Range2.62
2.81
52 Week Range0.12
8.69

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Stocklytics logo

Period: Next 12 Months

Predicted: just now

info

Analyzed by 2 Wall Street experts, Pyxis Tankers 's 12-month projections average at $4.50, spanning from a high of $6.00 to a low of $3.00. This signifies an 37.19% shift from the current price of $3.28.

Analyst Ratings

Buy

Buy
2
100.00%
Hold
0
0.00%
Sell
0
0.00%
Ratings from: March

Last updated: just now

Total: 2
info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

About InMed Pharmaceuticals (INM)

INM is a pharmaceutical company with a focus on developing and commercializing cannabinoid-based therapies. The company's primary product is INM-085, a potential treatment for the rare genetic disease epidermolysis bullosa. This condition causes the skin to be extremely fragile and prone to blistering and tearing. INM-085 is designed to alleviate the symptoms of the disease and improve patients' quality of life. In addition to this lead candidate, InMed has a pipeline of other cannabinoid-based therapies in various stages of development.
In terms of its stock price history, INM has experienced some volatility over the years. It initially went public in 2016, and since then, its stock price has had its ups and downs. However, there has been a general upward trend in recent years, reflecting the growing interest in cannabinoid-based therapies. Investors are optimistic about the potential of these products to address a wide range of medical conditions and the potential for significant revenue growth. INM's stock price is closely watched by investors and analysts in the pharmaceutical industry.
Show more
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Eric A. Adams B.S. Chem., M.I.B.
Headquarters
Vancouver
Employees
13
Exchange
NASDAQ
add InMed Pharmaceuticals to watchlist

Keep an eye on InMed Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is InMed Pharmaceuticals's (INM) price per share?

The current price per share for InMed Pharmaceuticals (INM) is $2.69. The stock has seen a price change of $0.03 recently, indicating a 1.12% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for InMed Pharmaceuticals (INM)?

For InMed Pharmaceuticals (INM), the 52-week high is $8.69, which is 223.69% from the current price. The 52-week low is $0.12, the current price is 2.12K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is InMed Pharmaceuticals (INM) a growth stock?

InMed Pharmaceuticals (INM) has shown an average price growth of -1.65% over the past three years. It has received a score of 96 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying InMed Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is InMed Pharmaceuticals (INM) stock price performance year to date (YTD)?

As of the latest data, InMed Pharmaceuticals (INM) has a year-to-date price change of -43.35%. Over the past month, the stock has experienced a price change of -16.09%. Over the last three months, the change has been -47.86%. Over the past six months, the figure is -52.16%.
help

Is InMed Pharmaceuticals (INM) a profitable company?

InMed Pharmaceuticals (INM) has a net income of -$7.68M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 23.94% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -198.46% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 11.18%, providing insight into the company's sales performance and growth. The gross profit is $1.1M. Operating income is noted at -$7.91B. Furthermore, the EBITDA is -$7.55M.
help

What is the market capitalization of InMed Pharmaceuticals (INM)?

InMed Pharmaceuticals (INM) has a market capitalization of $3.25M. The average daily trading volume is 2.72, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level